TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04794426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Previous studies have recommended that Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. the objective is useful in arresting early childhood caries (ECC)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hall Technique
Description: The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method.
Study: NCT06171230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing
Description: Using the LEC and PCL-5, emotionally charged images are selected at the onset of the EMDR intervention. Initially, events meeting the criteria for PTSD (A-criterion worthy events) are processed. Subsequently, pain-related experiences, including any distressing images, are addressed. If the emotional charge of the events diminishes (SUD=0) before the completion of the six EMDR sessions, the participant is categorized as an 'early completer,' and the post-assessment is conducted immediately. The duration of each EMDR session is 90 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention control phase
Description: Prior to EMDR, there is a two-week attention control phase. During this phase, the participant is asked to daily record their activities, emotions, and thoughts when experiencing pain. This information is further explored and evaluated in two sessions lasting 45 minutes each, involving in-depth discussions with the participant.
Study: NCT06513013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 25ml volume on each side (20ml of 0.25% bupivacaine plus 5ml of normal saline containing 500 mcg neostigmine.~A 22-gauge spinal needle will be advanced using the in-plane technique at the anterior axillary line, and the precise position of the needle tip between the internal oblique and transverse abdominis muscle will be visualized. To expand the plane, 2 mL of normal saline will be administered. Following the affirmation of a hypoechoic region on the USG image, the study solutions will be injected as per group allocation. Postoperatively,both groups of patients received an injection of paracetamol 1gm intravenously every 8th hourly as a part of multimodal analgesia and the patients will be evaluated for pain, nausea or vomiting in the post anaesthesia care unit at time 0 (time of completion of TAP block), 2, 4, 6,12 and 24 h by an investigator blinded to the group assignment. Whenever the NRS \>4, Nalbuphine 0.1 mg/kg IV will be administered as a rescue analgesic.
Study: NCT06215911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovinontrine (CRD-750)
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovinontrine (CRD-750)
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovinontrine (CRD-750)
Description: Tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally
Study: NCT05454215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical insufflation/exsufflation conventional
Description: Conventional settings in a commercially available chest physiotherapy device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation/exsufflation conventional
Description: Conventional settings in a commercially available chest physiotherapy device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical insufflation/exsufflation modified
Description: Modified settings in a commercially available chest physiotherapy device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation/exsufflation modified
Description: Modified settings in a commercially available chest physiotherapy device
Study: NCT06483607

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: M-TAPA block with bupivacaine 25%
Description: Following sterile conditions for bilateral M-TAPA block application, the transducer will be inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle will be created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip will be placed just below the chondrium and saline (5 ml) will be injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine will be administered for each group for a total of 40 ml of local anesthetic. Blocks will be applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose will be applied to the contralateral side for each group of M-TAPA patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAP block with bupivacaine 25%
Description: After the necessary sterilization conditions established, the linear ultrasound probe will be placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum will be identified. As the tip of the 80 mm sonovisible needle passes through the muscular layers and fascia, the needle will be advanced in a controlled manner. After receiving the click sensation (passage of the fascia of the internal oblique muscle), the location of the needle will be fixed and 20 ml of 0.25% bupivacaine will be injected between internal oblique and transversus abdominis muscles. Same procedure will be performed to the other site. (40 ml local anesthetics in total)
Study: NCT04976959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Fiber supplement
Description: The supplement consists of a mixture of soluble fibers (from inulin and fibersol-2) and insoluble fibers (from oat bran, corn bran, wheat bran and sorghum bran) and it will be consumed as a drink.
Study: NCT04828564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin Capsules
Description: Ribavirin 200 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Favipiravir 200 mg tablets
Study: NCT05861362

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Curative radiotherapy
Description: Curative radiotherapy as indicated by the patient's disease and prescribed by the treating radiation oncologist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5:2 intermittent fasting
Description: Two nonconsecutive days of fasting per week that could be chosen freely according to the patient's weekly schedule.
Study: NCT05796648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RN-CHeFRx
Description: The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
Study: NCT03625986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine-Containing Electronic Cigarette
Description: The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The experimental group in this project will receive a SREC device with liquid containing 58 mg/mL of nicotine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Nicotine Electronic Cigarette
Description: The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The placebo group in this project will receive a SREC device with liquid containing 0 mg/mL of nicotine.
Study: NCT04881227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chatbot on COVID-19 vaccine hesitancy
Description: This intervention will provide to participants information on COVID-19 vaccine hesitancy consisting of the possibility of accessing a long series of questions and answers online about this vaccination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: This control intervention will provide to participants a brief text decribing the way vaccines works.
Study: NCT06151535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELAPR002f Injectable Gel
Description: Intradermal Injections
Study: NCT06053164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exertional Oxygen
Description: Use of a portable oxygen concentrator for exertional activities lasting \>2 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exertional Oxygen
Description: Use of a portable oxygen concentrator for exertional activities lasting \>2 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Support
Description: Participants will receive disease-specific educational material (Living Well with Pulmonary Fibrosis: Oxygen), and will have scheduled phone appointments with a certified respiratory educator after 1, 3, and 5 weeks of oxygen therapy in order to address individual barriers to oxygen use and facilitate the optimal use of portable oxygen.
Study: NCT06114212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dTMS stimulation via the H4 coil
Description: Deep repetitive transcranial magnetic stimulation (dTMS) uses transient electromagnetic fields to stimulate the brain and is approved by Health Canada and the FDA for the treatment of depression, anxious depression, obsessive-compulsive disorder, and tobacco use disorder. Compared to the traditional TMS, dTMS is able to target brain depths ranging from 2 to 6 cm. With the use of various H-coils, dTMS has been used to target specific neural networks with the aim of producing desired clinical effects in psychiatric populations. The intervention in this study is the H4 dTMS coil which stimulates the lateral prefrontal cortex and the insula in the brain.
Study: NCT05747963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: software-delivered CBT-I
Description: The automated software called 'resleep' incorporates all core elements of CBT-I: sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene and education, tailoring content based on each participant's reported baseline sleep function and sleep progress. The 6-week treatment includes 42 times of intervention.
Study: NCT06288841

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine injection
Description: Ultrasound-guided bilateral QLB2 was performed using Ropivacaine injection prior to anesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: Ultrasound-guided bilateral QLB2 was performed using Bupivacaine liposome injection prior to anesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: Ultrasound-guided bilateral QLB2 was performed using Bupivacaine liposome injection prior to anesthesia induction
Study: NCT05747963

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: online PE
Description: Subjects in the control group will receive non-tailored information about insomnia and sleep health education content using the Wechat Official Account.
Study: NCT06288841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: Ultrasound-guided bilateral QLB2 was performed using Bupivacaine liposome injection prior to anesthesia induction
Study: NCT05510128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist management
Description: When a patient comes to the pharmacy with signs of urinary burning, the following will follow:~* Completion of the acute cystitis symptoms score (ACSS) questionnaire.~* Measure the temperature.~* Perform a urine dipstick.~If the patient's temperature is normal, the urine dipstick is positive, and the absence of pain in the lumbar fossa is verified, the pharmacist can dispense an appropriate antibiotic himself. A reminder of the hygienic-dietary rules is also issued, and a communication to the patient's general practitioner will be made.
Study: NCT05041153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given by PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV
Study: NCT06194448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80 mg daily (or 40 mg daily for dose reduction)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin; Pemetrexed or Paclitaxel
Description: Pemetrexed (500 mg/m2 to be administered on Day 1 of every 3-week cycle for 2 cycles) or Paclitaxel (175 mg/m2 on Day 1 of every 3-week cycle for 2 cycles) PLUS Cisplatin (75 mg/m2) or Carboplatin (AUC5) to be administered on Day 1 of every 3--week cycle for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patients must have received a total dose of radiation of 60 Gy ± 10% (54 to 66 Gy) as part of the chemoradiation therapy. It is recommended but not required that patients have a:~* Mean lung dose \< 20 Gy and/or V20 \< 35%~* Mean oesophagus dose \< 34 Gy~* Heart V50 \< 25%, V30 \< 50%, and V45 \< 35%
Study: NCT05771779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Cholera Vaccine (OCV)
Description: Bivalent, Killed, Whole Cell Oral Cholera Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Cholera Vaccine (OCV)
Description: Bivalent, Killed, Whole Cell Oral Cholera Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Cholera Vaccine (OCV)
Description: Bivalent, Killed, Whole Cell Oral Cholera Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid Conjugate Vaccine (TCV)
Description: Vi-polysaccharide conjugated to tetanus toxoid, Vi-TT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid Conjugate Vaccine (TCV)
Description: Vi-polysaccharide conjugated to tetanus toxoid, Vi-TT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid Conjugate Vaccine (TCV)
Description: Vi-polysaccharide conjugated to tetanus toxoid, Vi-TT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella (MR)
Description: Live attenuated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella (MR)
Description: Live attenuated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella (MR)
Description: Live attenuated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella (MR)
Description: Live attenuated vaccine
Study: NCT06160895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334 tablets
Description: TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334 tablets
Description: TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334 tablets
Description: TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQ-A3334 placebo tablets
Description: TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQ-A3334 placebo tablets
Description: TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQ-A3334 placebo tablets
Description: TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.
Study: NCT05771779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella (MR)
Description: Live attenuated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella (MR)
Description: Live attenuated vaccine
Study: NCT04927130

Intervention type: DIAGNOSTIC_TEST
Intervention: ARNA Breast
Description: A specific DNA fragments and globulins will be detected in blood plasma.

Intervention type: DIAGNOSTIC_TEST
Intervention: ARNA Breast
Description: A specific DNA fragments and globulins will be detected in blood plasma.
Study: NCT05520463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacral lateral branch radiofrequency ablation under ultrasound guidance
Description: Sacral lateral branch radiofrequency ablation will be performed under ultrasound guided approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral lateral branch radiofrequency ablation under fluoroscopy guidance
Description: Sacral lateral branch radiofrequency ablation will be performed under fluoroscopy guided approach.
Study: NCT05112809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Stimulation System (CSS)
Description: Cochlear stimulation with surround sound and noise cancellation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Stimulation System (CSS)
Description: Cochlear stimulation with surround sound and noise cancellation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Stimulation System (CSS)
Description: Cochlear stimulation with surround sound and noise cancellation
Study: NCT04964999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will undergo an exercise program during the 2-week bed rest period.
Study: NCT05801289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Giving the drug to group Q
Study: NCT05156372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Participants will perform high-intensity aerobic and resistance exercise
Study: NCT04777786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Individualized physical therapy treatments will be provided based on impairments identified during assessments. Treatment may include but is not limited to the following: passive, assisted and active ROM, manual therapy, soft tissue massage, myofascial release, therapeutic activities and exercise and patient education. Treatment duration and frequency will be specific to each patient, providing personalized care. This type of intervention is considered a pragmatic approach, which will allow for generalization of the results due to the similarity with clinical practice.71 Pilot data indicates women will receive physical therapy intervention 1-2x/week for 3-6 weeks beginning \~4 weeks after surgery (x̄=10 visits).
Study: NCT06214286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: Shockwave therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping
Description: Kinesio taping application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: conventional physical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: conventional physical therapy
Study: NCT05777967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human autologous synovial stem cells
Description: A single injection of 1.5 to 9.0 x 10\^7 human autologous synovial stem cells under arthroscopy
Study: NCT05767229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol 0.2 mg/kg for 1.5 hrs
Study: NCT06158204

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: Participants will receive guidance on when and what to eat and when to sleep and be physically active. Additionally, participants will be provided with whey protein isolate powder to be mixed with water and grain-based snack bars to be consumed primarily during work shifts. Lean body mass (kg) will be used to prescribe total caloric (\~30kcal/kg lean mass) and protein (2g/kg lean mass) needs and sleep/rest goals will be 6-8 hours per 24 hour day
Study: NCT05976971

Intervention type: OTHER
Group type: OTHER
Intervention: 7T MRI
Description: Subjects will have a 7T MRI and questionnaires on the only day of clinical study.

Intervention type: OTHER
Group type: OTHER
Intervention: 7T MRI
Description: Subjects will have a 7T MRI and questionnaires on the only day of clinical study.
Study: NCT06158204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants will receive guidance on when and what to eat and when to sleep and be physically active. Additionally, participants will be provided with whey protein isolate powder to be mixed with water and grain-based snack bars to be consumed primarily during work shifts. Lean body mass (kg) will be used to prescribe total caloric (\~30kcal/kg lean mass) and protein (2g/kg lean mass) needs and sleep/rest goals will be 6-8 hours per 24 hour day
Study: NCT06020625

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Diagnostic Test
Description: In order to proceed with molecular characterization, the tumor sample already taken for histological diagnosis will undergo DNA and RNA extraction, which will be analyzed for qualitative and quantitative evaluation. Based on the quantitative data, the method to be used for profiling will be decided.~Multigenic genomic profiling will be performed for each patient on already taken tumor tissue using different panels depending on the quality and quantity of nucleic acids, in particular the following will be used: comprehensive Genome Profiling (CGP, ≥500 genes), if at least 40 ng of material is available; Profiling with identification of actionable mutations by targeted sequencing with panels of size \>50 genes, if \<40 ng material available.